Bioinorganic interactionsCollection sécurité. 1984, Vol 15, Num 3-4, pp 448-453, issn 0538-4818Article

Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives : mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitorsISHIDA, R; MIKI, T; NARITA, T et al.Cancer research (Baltimore). 1991, Vol 51, Num 18, pp 4909-4916, issn 0008-5472Conference Paper

Evidence from studies with intact mammalian cells that merbarone and bis(dioxopiperazine)s are topoisomerase II poisonsSNYDER, Ronald D.Drug and chemical toxicology (New York, NY. 1978). 2003, Vol 26, Num 1, pp 15-22, issn 0148-0545, 8 p.Article

Bis(2,6-dioxopiperaxine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosisONISHI, Y; AZUMA, Y; KIZAKI, H et al.Biochemistry and molecular biology international. 1994, Vol 32, Num 1, pp 115-122, issn 1039-9712Article

Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor modelsNARITA, T; FYAGUCHI, S.-I; KOMATSU, T et al.Cancer chemotherapy and pharmacology. 1990, Vol 26, Num 3, pp 193-197, issn 0344-5704, 5 p.Article

The effects of ICRF-154 in combination with other anticancer agents in vitroKANO, Y; NARITA, T; SUZUKI, K et al.British journal of cancer. 1992, Vol 66, Num 2, pp 281-286, issn 0007-0920Article

Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivativesTANABE, K; IKEGAMI, Y; ISHIDA, R et al.Cancer research (Baltimore). 1991, Vol 51, Num 18, pp 4903-4908, issn 0008-5472Conference Paper

Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasisXUE, Y; GUO, Y; XIE, X et al.Leukemia research. 1997, Vol 21, Num 2, pp 107-109, issn 0145-2126Article